A New Step Forward: Extending the GT-02287 Trial in Parkinson’s

Gain Therapeutics is extending its Phase 1b clinical trial of GT-02287, a potential new treatment for Parkinson’s disease, to nine months. This extension is important because it allows researchers to better understand the long-term safety, tolerability, and potential benefits of the drug. For people living with Parkinson’s, the possibility of a therapy that targets underlying causes—rather than just managing symptoms—offers meaningful hope. How GT-02287 Works GT-02287 is a small molecule therapy designed to restore the function of GCase, an enzyme that helps recycle fatty molecules in the brain. Mutations in the GBA1 gene can reduce GCase activity, leading to the buildup of toxic deposits, including misfolded alpha-synuclein, a hallmark of Parkinson’s. By binding to and stabilizing GCase, GT-02287 aims to prevent this harmful accumulation and protect brain cells. Early Signs of Promise In preclinical studies, GT-02287 reduced alpha-synuclein clumps, lowered inflammation, preserved nerve cells, improved motor function, and supported complex behaviors. In an earlier Phase 1 trial with healthy volunteers, GT-02287 safely reached the brain and partly restored GCase activity. In the current Phase 1b trial, 21 people with early Parkinson’s (idiopathic or with GBA1 mutations) took GT-02287 daily for three months. More than half have now chosen to continue in the nine-month extension. What’s Next Interim results will be presented at the Movement Disorders Society International Congress in October 2025, with more data expected later in the year. Researchers will track both clinical outcomes (like changes on the MDS-UPDRS, a scale that measures symptoms and function) and biomarkers in the brain and blood. The Bigger Picture While GT-02287 is still in the early stages of testing, its focus on addressing one of the biological drivers of Parkinson’s sets it apart from standard symptom-focused treatments. If future results confirm its benefits and safety, GT-02287 could represent a new class of therapies—ones that not only help with symptoms but also protect the brain from ongoing damage.